Overzicht belangen werkgroepleden
Uit Richtlijnen HIV
(Verschil tussen bewerkingen)
(Nieuwe pagina aangemaakt met '<span style="background-color: #ffff00">'''HIER OVERZICHT VAN INGEVULDE BELANGENVERKLARINGEN INVOEGEN (MARISKA)'''</span>') |
|||
Regel 1: | Regel 1: | ||
- | <span style="background-color: #ffff00"> | + | {| border="1" cellspacing="1" cellpadding="1" width="100%" |
+ | |- | ||
+ | | '''Naam''' | ||
+ | | '''Firma''' | ||
+ | | '''Consultatie/advisering''' | ||
+ | | '''Wetenschappelijk onderzoek''' | ||
+ | | '''Congres/andere reis''' | ||
+ | | '''Cursus''' | ||
+ | |- | ||
+ | | Kees Brinkman | ||
+ | | Viiv | ||
+ | | x | ||
+ | | | ||
+ | | x | ||
+ | | x | ||
+ | |- | ||
+ | | | ||
+ | | BMS | ||
+ | | x | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | MSD | ||
+ | | x | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | Gilead | ||
+ | | x | ||
+ | | | ||
+ | | x | ||
+ | | x | ||
+ | |- | ||
+ | | | ||
+ | | Roche | ||
+ | | | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | Abbott | ||
+ | | x | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | Jansen-Tibotec | ||
+ | | x | ||
+ | | | ||
+ | | x | ||
+ | | x | ||
+ | |- | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | | Mariska Tuut | ||
+ | | Geen | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | | Suzanne Geerlings | ||
+ | | MSD | ||
+ | | x | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | GSK | ||
+ | | x | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | BMS | ||
+ | | x | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | Gilead | ||
+ | | | ||
+ | | | ||
+ | | x | ||
+ | | x | ||
+ | |- | ||
+ | | | ||
+ | | Abbott | ||
+ | | x | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | Jansen Cilag (Tibotec) | ||
+ | | | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | Pfizer | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | x | ||
+ | |- | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | | <span style="background-color: #ffff00">Jet Gisolf</span> | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | | Gerrit Schreij | ||
+ | | Viiv Healthcare | ||
+ | | x | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | Gilead | ||
+ | | | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | Tibotec | ||
+ | | | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | Roche | ||
+ | | | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | MSD | ||
+ | | | ||
+ | | | ||
+ | | x | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |} |
Versie op 19 mei 2010 08:16
Naam | Firma | Consultatie/advisering | Wetenschappelijk onderzoek | Congres/andere reis | Cursus |
Kees Brinkman | Viiv | x | x | x | |
BMS | x | ||||
MSD | x | x | |||
Gilead | x | x | x | ||
Roche | x | ||||
Abbott | x | x | |||
Jansen-Tibotec | x | x | x | ||
Mariska Tuut | Geen | ||||
Suzanne Geerlings | MSD | x | x | ||
GSK | x | ||||
BMS | x | x | |||
Gilead | x | x | |||
Abbott | x | x | |||
Jansen Cilag (Tibotec) | x | ||||
Pfizer | x | ||||
Jet Gisolf | |||||
Gerrit Schreij | Viiv Healthcare | x | x | ||
Gilead | x | ||||
Tibotec | x | ||||
Roche | x | ||||
MSD | x | ||||